DSIP and Emideltide: old human studies do not prove a modern sleep peptide.
DSIP has a defined nine-amino-acid identity and historical human research. The current record does not establish chronic-insomnia treatment, a dependable deep-sleep benefit, an opioid-withdrawal treatment, a subcutaneous dosage, or a well-characterized safety profile. This guide keeps every claim in its proper evidence lane.
Does DSIP improve sleep? The historical signal is not a proven treatment effect.
FDA identifies Emideltide, also called delta sleep-inducing peptide or DSIP, as a nonapeptide. PubChem lists formula C35H48N10O15 and molecular weight 848.8 for the indexed compound.
Old human studies used intravenous administration. FDA judged the chronic-insomnia evidence preliminary and inconclusive, found no effectiveness study for the proposed subcutaneous route, and found no subcutaneous safety data. A modern seller vial cannot borrow certainty from those old records.
Read the DSIP and Emideltide record in four fields.
This is a sourced status snapshot, not a safety score, treatment recommendation, or seller certification. Each field links back to the detailed record below.
Old intravenous studies
FDA found 209 exposed subjects across short studies, but judged effectiveness evidence insufficient for all three reviewed uses.
Inspect the human evidenceNot clinically established
Sleep and withdrawal observations do not establish insomnia treatment, deep-sleep benefit, or a current subcutaneous regimen.
Audit the popular claimsNo FDA-approved product
PCAC recommended against inclusion 6-7-1 for each reviewed form. The committee advice is nonbinding and final FDA action is pending.
Check status and destination routesDated US price boards
Identity, old IV studies, treatment claims, SC safety, and FDA status answer different questions.
Keeping the route and product visible prevents an old research signal from becoming a modern dosage, efficacy, safety, or seller-vial claim.
A nine-amino-acid peptide with two reviewed forms
Emideltide is also called delta sleep-inducing peptide or DSIP. FDA describes a nonapeptide sequence of Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and evaluates the free base and acetate as different bulk drug substances.
Human exposure exists, but it is old and intravenous
FDA identified published human exposure involving intravenous Emideltide. Those records are useful, but they are small, old, methodologically limited, and do not establish the proposed subcutaneous route found in current compounding claims.
Sleep and withdrawal signals remain inconclusive
FDA judged the intravenous effectiveness evidence insufficient for chronic insomnia, narcolepsy, and opioid withdrawal. The insomnia work was preliminary, narcolepsy relied on a case report, and withdrawal reports lacked adequate controls.
No subcutaneous safety record was identified
FDA summarized 209 subjects who received intravenous Emideltide for one to fifteen days, but found no subcutaneous safety data. Withdrawal reports included transient headache, nausea, vertigo, and hypotension, while aggregation, impurity, stability, and immunogenicity questions remain unresolved.
Committee recommended against inclusion, with final FDA action pending
Neither reviewed form is a component of an FDA-approved drug. FDA staff proposed not adding either form to the 503A Bulks List, and PCAC recommended against inclusion in separate 6-7-1 votes on July 24. The committee advice is nonbinding and is not a final FDA determination.
What the DSIP record shows, and what it cannot prove.
Each popular claim is paired with the strongest relevant signal and the inference that still fails.
DSIP improves deep sleep
Old intravenous studies reported sleep-related observations, which is why DSIP remains associated with sleep in research and marketing language.
FDA judged the chronic-insomnia record preliminary and inconclusive. Sleep-stage signals do not establish dependable clinical benefit, a current product, or the subcutaneous route.
DSIP treats chronic insomnia
FDA reviewed chronic insomnia as a nominated use and identified old human intravenous reports.
FDA found the effectiveness evidence insufficient, and major sleep guidelines reviewed in the briefing do not discuss Emideltide as an insomnia treatment.
DSIP treats opioid withdrawal
Two old reports described withdrawal treatment in hospitalized patients after intravenous DSIP.
The reports were uncontrolled or open label, lacked an adequate comparator, and cannot establish effectiveness, safe substitution for evidence-based care, or a current dosage protocol.
DSIP is side-effect free
Some early insomnia reports did not identify significant adverse effects during short intravenous exposure.
Withdrawal reports included headache, nausea, vertigo, and hypotension. FDA found no subcutaneous safety data and unresolved injectable product-quality risks.
A natural peptide means every vial is equivalent
DSIP has a reported endogenous-peptide history and a defined indexed molecular identity.
That does not prove a seller vial's form, sequence, concentration, purity, sterility, stability, aggregation, custody, or equivalence to material used in an old intravenous study.
DSIP is FDA approved or has been banned
FDA evaluated the free-base and acetate forms through a public 503A bulk-substance process. PCAC recommended against including both forms in separate 6-7-1 votes.
Neither form is an FDA-approved drug, but a nonbinding committee recommendation is not itself a final FDA determination, a blanket ban, or a universal worldwide legal verdict.
Five records, with route and study design kept visible.
A registry snapshot, an FDA synthesis, small IV studies, and uncontrolled withdrawal reports are not interchangeable evidence.
Emideltide evidence and safety synthesis
FDA judged the intravenous effectiveness evidence insufficient for insomnia, narcolepsy, and opioid withdrawal, found no subcutaneous safety data, and identified unresolved injectable quality risks.
Exact Emideltide and Delta Sleep-Inducing Peptide search
Zero exact-name records were returned on July 21, 2026. That dated registry result does not erase published historical human research, which is why the records are shown separately.
Delta sleep-inducing peptide in insomnia
The small reports generated sleep-related hypotheses. FDA's later synthesis characterizes the clinical evidence as preliminary and inconclusive rather than proof of insomnia treatment.
DSIP in withdrawal syndromes
The report described withdrawal observations without a randomized controlled comparator. FDA also preserves reported headache, nausea, vertigo, and hypotension in this evidence lane.
Earlier DSIP withdrawal report
The report lacked a controlled comparator, and 27 percent of enrolled patients were lost or considered unsuitable for evaluation. It cannot establish a reliable treatment effect.
An intravenous paper does not validate a subcutaneous listing.
Route changes exposure, formulation requirements, product risks, and the evidence needed to support safety and effectiveness.
Intravenous Emideltide
FDA found short human IV exposure across old sleep and withdrawal records. The agency still judged effectiveness evidence insufficient for the reviewed uses.
Read the FDA synthesis →Subcutaneous Emideltide
FDA found no effectiveness study and no safety data using the proposed SC route. Historical IV experience cannot fill that gap.
Resolve the product category →Seller-labelled DSIP 5 mg
Peptide Local tracks 3 exact-size US research listings and 2 confirmed in-stock rows. This is market data, not product authentication or clinical validation.
Compare the dated price rows →The July 24 committee result is recorded, but it is not the final step.
Peptide Local dates each stage so a staff proposal or committee recommendation is not silently reported as an approval, ban, or final decision.
Do not add either Emideltide form
FDA staff proposed not adding Emideltide free base or Emideltide acetate to the 503A Bulks List based on the reviewed record.
Read the briefing →PCAC recommended against inclusion
Both form-specific questions received reported 6-7-1 votes. The committee advice is nonbinding and does not itself create final FDA action or a blanket ban.
Open the verified vote record →Final FDA determination
FDA can complete its review after considering committee input. The status should change only when the agency publishes the later record.
Track all seven substances →DSIP access and product status depend on the exact destination.
There is no responsible one-line worldwide verdict. Check the precise substance and form, medicine authorization, prescription and compounding rules, import route, seller or pharmacy status, and destination. These routes locate official records without pretending that a generic country page proves DSIP authorization.
Ten DSIP and Emideltide questions, answered from the current record.
This is educational reporting, not medical advice, a prescription, a product endorsement, a withdrawal plan, or a use protocol.
What is DSIP or Emideltide?
DSIP means delta sleep-inducing peptide. FDA calls the substance Emideltide and describes a nine-amino-acid sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. PubChem lists formula C35H48N10O15 and molecular weight 848.8 for the indexed compound. FDA evaluates Emideltide free base and Emideltide acetate as different bulk drug substances, so a short label does not fully resolve the material or formulation.
Does DSIP improve deep sleep?
Old intravenous studies reported sleep-related observations, but the current cited record does not establish a dependable deep-sleep benefit. FDA reviewed the historical work and judged the chronic-insomnia evidence preliminary and inconclusive. A sleep-stage observation in a small old study cannot determine whether a current seller-labelled vial improves sleep quality, daytime function, or clinical insomnia.
Does DSIP treat chronic insomnia?
FDA found insufficient evidence that intravenous Emideltide treats chronic insomnia and no effectiveness study using the proposed subcutaneous route. The FDA briefing also notes that major American sleep guidelines it reviewed do not discuss Emideltide. That does not prove the molecule has no biological activity. It means an insomnia treatment claim is not established by the current human evidence record.
What did the human DSIP studies show?
The historical human record includes small intravenous sleep studies, one narcolepsy case report, and uncontrolled withdrawal reports. FDA counted 209 subjects who received intravenous Emideltide across studies for one to fifteen days. The agency judged effectiveness evidence insufficient for all three reviewed uses. The route, age, size, controls, outcome methods, and follow-up of those studies limit what can be inferred today.
Does DSIP help opioid or alcohol withdrawal?
Old uncontrolled reports described withdrawal observations after intravenous DSIP, but they do not establish an effective treatment. The studies lacked adequate randomized comparators, relied on open clinical evaluation, and had important attrition or reporting limits. They also cannot support replacing evidence-based medical withdrawal care, which can involve serious risks and should not be self-managed from a peptide listing.
What are the reported DSIP side effects?
Some short insomnia reports did not identify significant adverse effects, while withdrawal studies reported transient headache, nausea, vertigo, and hypotension. FDA found no safety data for the proposed subcutaneous route and identified unresolved risks involving aggregation, impurities, characterization, stability, and immunogenicity. The absence of a complete adverse-event list is an evidence gap, not proof that side effects are rare.
Is DSIP FDA approved?
No FDA-approved drug contains Emideltide free base or Emideltide acetate according to the July 2026 FDA record. FDA staff proposed not adding either form to the 503A Bulks List, and PCAC recommended against inclusion in separate 6-7-1 votes on July 24. The committee advice is nonbinding. FDA approval of a drug, eligibility for use as a compounding bulk substance, and a seller's research listing are separate records.
Did FDA ban DSIP?
The current July 2026 record is not a final blanket ban. PCAC recommended against including both Emideltide forms after separate 6-7-1 votes on July 24, but the recommendation is nonbinding and FDA may issue a later final determination. Country authorization, import rules, professional supply, and seller status also differ by destination, so a US federal compounding process is not a worldwide legal verdict.
What is the correct DSIP dosage?
The current evidence does not support a Peptide Local dosing recommendation. Historical human studies used intravenous administration, while the FDA nomination involved a proposed subcutaneous route for which FDA found no effectiveness or safety study. A seller vial, historical study material, compounded preparation, and approved medicine are not interchangeable, and dose cannot repair those identity and evidence gaps.
Can you buy DSIP legally?
Public research listings can exist even when there is no FDA-approved drug, but a visible offer does not establish lawful human use, import eligibility, pharmacy authorization, or product authenticity. Resolve the exact free-base or acetate form, intended product category, seller or pharmacy, destination, and official regulator record. The price board documents US research-market observations only and does not convert them into medical availability.
A molecular identity is not a finished product, proven sleep benefit, or personal regimen.
Emideltide free base, Emideltide acetate, endogenous-peptide research, an intravenous study intervention, a proposed subcutaneous compounded preparation, and a seller-labelled vial can differ in identity, formulation, concentration, impurities, aggregation, sterility, exposure, and risk.
FDA approval, 503A list status, country authorization, import status, seller availability, product authentication, and clinical evidence are separate records. No single source here supplies a personal sleep, withdrawal, or treatment decision.